1-(3,4-dichlorophenyl)-2-thiourea, also known as **DCP-TU** or **3,4-Dichlorophenylthiourea**, is an organic compound with the chemical formula C7H5Cl2N3S.
**Structure and Properties:**
* **Structure:** It consists of a thiourea group (NH-CS-NH) attached to a 3,4-dichlorophenyl ring.
* **Appearance:** It is typically a white to off-white solid.
* **Solubility:** It is sparingly soluble in water but soluble in organic solvents.
**Importance in Research:**
DCP-TU has been investigated in various research fields, including:
**1. Pesticide Research:**
* **Fungicide:** DCP-TU exhibits fungicidal activity against a broad spectrum of fungal pathogens. Its mechanism of action involves inhibiting the synthesis of fungal sterols, which are essential for cell membrane integrity.
* **Herbicide:** DCP-TU also shows herbicidal properties, interfering with plant growth and development.
* **Antimicrobial Activity:** Some studies have indicated antimicrobial activity against bacteria and other microorganisms.
**2. Pharmaceutical Research:**
* **Anti-cancer activity:** Research suggests that DCP-TU may possess anti-cancer properties, potentially targeting various cancer cell lines.
* **Anti-inflammatory activity:** It has been shown to exhibit anti-inflammatory effects in animal models.
* **Antioxidant properties:** DCP-TU may act as an antioxidant, scavenging free radicals and protecting cells from damage.
**3. Materials Science:**
* **Organic semiconductors:** DCP-TU has potential as a building block for organic semiconductors due to its ability to form stable films and exhibit electrical conductivity.
**4. Environmental Research:**
* **Bioremediation:** Studies explore the use of DCP-TU in bioremediation processes for the removal of pollutants from soil and water.
**Note:** It's important to emphasize that the research on DCP-TU is still ongoing, and further investigations are necessary to fully understand its properties and potential applications. Its use in practical applications may be limited due to its toxicity and potential environmental impact.
1-(3,4-dichlorophenyl)-2-thiourea: structure given in first source; used for studying the urea-facilitated transport system in the frog [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 710776 |
| CHEMBL ID | 1425001 |
| SCHEMBL ID | 526255 |
| SCHEMBL ID | 10788726 |
| MeSH ID | M0216279 |
| Synonym |
|---|
| AC-15681 |
| EN300-28841 |
| smr000460619 |
| MLS000861835 |
| n-(3,4-dichlorophenyl)thiourea |
| 1-(3,4-dichlorophenyl)-2-thiourea |
| 19250-09-0 |
| MAYBRIDGE1_007486 |
| AKOS000113772 |
| HMS562M06 |
| (3,4-dichlorophenyl)thiourea |
| 3,4-dichlorophenylthiourea |
| NCGC00246699-01 |
| 3,4-dichlorophenylthiourae |
| A813583 |
| (3,4-dichlorophenyl)thiourea;1-(3,4-dichlorophenyl)thiourea |
| einecs 242-919-1 |
| HMS2782G12 |
| amino[(3,4-dichlorophenyl)amino]methane-1-thione |
| thiourea,n-(3,4-dichlorophenyl)- |
| FT-0614259 |
| FT-0614260 |
| BBL023130 |
| 1-(3,4-dichlorophenyl)thiourea |
| STL362909 |
| SCHEMBL526255 |
| (3,4-dichloro-phenyl)-thiourea |
| CCNCITSJXCSXJY-UHFFFAOYSA-N |
| (3,4-dichlorophenyl)-thiourea |
| SCHEMBL10788726 |
| CHEMBL1425001 |
| thiourea, (3,4-dichlorophenyl)- |
| DTXSID90172846 |
| mfcd00004935 |
| thiourea, n-(3,4-dichlorophenyl)- |
| J-012450 |
| DS-7379 |
| O10265 |
| SB80142 |
| CS-0306667 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 17.7828 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 10.3910 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 5.0119 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 5.0119 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 5.0119 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||